Building strategic adjacencies on shared biology: Q&A with Tony Wood

GSK is entering a period of transition as Luke Miels prepares to succeed CEO Emma Walmsley. Yet the leadership change doesn’t appear to herald a major shift in R&D strategy. CSO Tony Wood continues to push toward a more focused pipeline, while resisting the pull toward drug classes chased by “the herd.”

In an interview with BioCentury, Wood described what he expects will be a smooth transition for the R&D organization when Walmsley steps down in January. Although she’s led GSK plc (LSE:GSK; NYSE:GSK) for eight years, her successor, Chief Commercial Officer Miels, has been working closely with Wood for years on late-stage clinical and business development decisions...